Tucatinib Triplet Gains FDA Approval for HER2-Positive Breast Cancer Maintenance
The FDA has approved a combination of tucatinib, trastuzumab, and pertuzumab for first-line maintenance treatment in HER2-positive breast cancer that cannot be removed surgically or has spread. The decision covers use of Tukysa as part of this three-drug regimen.
The FDA has approved a three-drug regimen for first-line maintenance in HER2-positive breast cancer that cannot be surgically removed or has spread. The combination includes tucatinib, sold as Tukysa, along with trastuzumab and pertuzumab. The agency’s decision specifically covers Tukysa as part of this regimen. This places the approval within the maintenance phase of treatment for an advanced or inoperable form of breast cancer, where therapy is matched to the tumor’s HER2 status. The news reflects continued drug development around combination regimens for this disease setting.
For patients with HER2-positive breast cancer that cannot be removed surgically or has spread, this approval may broaden first-line maintenance options. Clinicians and patients could have another three-drug regimen to consider, potentially affecting treatment planning and access discussions. Because the decision is specific to this setting, its societal reach may be concentrated among those with this diagnosis and their caregivers. How much it changes outcomes or costs may depend on uptake, coverage, and clinical judgment.